ROCO
8403
Market cap82mUSD
Oct 08, Last price
19.05TWD
1D
1.06%
1Q
-1.30%
Jan 2017
-18.49%
IPO
-26.87%
Name
ShareHope Medicine Co Ltd
Chart & performance
P/E
18.50
P/S
0.60
EPS
1.03
Div yield, %
2.62%
Shrs. gr., 5y
-3.47%
Rev. gr., 5y
1.23%
Revenues
4.36b
+0.74%
Net income
142m
-29.17%
CFO
364m
+36.54%
Dividend
Aug 25, 20260.6 TWD/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
ShareHope Medicine Co., Ltd., a company based in Taiwan, delivers a wide array of integrated healthcare solutions. Its operations encompass health management and administrative services, the provision of skilled medical professionals for staffing needs, and the distribution of various medical, pharmaceutical, and general health-related devices. The company also offers remote healthcare, often referred to as telemedicine, and facilitates the rental of essential medical equipment. ShareHope Medicine Co., Ltd. was established in 2003 and operates from its headquarters in Taoyuan City, Taiwan.
Key people
Hong-Ren Yang
Chairman of the Board, Chief Executive Officer · since 2020
Vice Chairman of the Board · since 2020
Lanying Fu
Deputy General Manager-General Manager's Office · since 2024
Weiguang He
Deputy General Manager · since 2020
Qingjun Huang
Deputy General Manager · since 2011
Yangren Lai
Deputy General Manager-Medicine Distribution & Service · since 2009
Yiquan Lin
Deputy General Manager-Strategy and Business · since 2011
Jiaxiang Shen
Deputy General Manager-Pharmaceutical Distribution · since 2011
Mingxun Wu
Deputy General Manager-Heal Management & Human Resources · since 2008
Yufang Cai
Corporate Governance Officer · since 2024
Siming Gu
Chief Strategy Officer · since 2020
Fangyu Lin
Head of Finance · since 2025
Huiwen Peng
Manager-Accounting · since 2011
Chang-Rong Chang
Director · since 2007
Qingwen Liu
General Manager, Director · since 2021
Chih-Li Sun
Director · since 2018
Caibi Yang Chen
Director · since 2017
Independent Director · since 2021
Su-Sing Li
Independent Director
Gen-Zai Wu
Independent Director · since 2018
Valuation
Title TWD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||||
Revenues | |||||||
Cost of revenue | |||||||
Unusual Expense (Income) | |||||||
NOPBT | |||||||
NOPBT Margin | |||||||
Operating Taxes | |||||||
Tax Rate | |||||||
NOPAT | |||||||
Net income | |||||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | |||||||
BB yield | |||||||
| Debt | |||||||
Debt current | |||||||
Long-term debt | |||||||
Deferred revenue | |||||||
Other long-term liabilities | |||||||
Net debt | |||||||
| Cash flow | |||||||
Cash from operating activities | |||||||
CAPEX | |||||||
Cash from investing activities | |||||||
Cash from financing activities | |||||||
FCF | |||||||
| Balance | |||||||
Cash | |||||||
Long term investments | |||||||
Excess cash | |||||||
Stockholders' equity | |||||||
Invested Capital | |||||||
ROIC | |||||||
ROCE | |||||||
| EV | |||||||
Common stock shares outstanding | |||||||
Price | |||||||
Market cap | |||||||
EV | |||||||
EBITDA | |||||||
EV/EBITDA | |||||||
Interest | |||||||
Interest/NOPBT | |||||||